207 related articles for article (PubMed ID: 35254477)
1. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
[TBL] [Abstract][Full Text] [Related]
2. [Expression pattern of the histone lysine demethylase family and its potential role in bladder cancer: a multi-omics analysis].
Fu X; Yu G; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1822-1831. PubMed ID: 36651250
[TBL] [Abstract][Full Text] [Related]
3. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
Lee J; Kim JS; Cho HI; Jo SR; Jang YK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
[TBL] [Abstract][Full Text] [Related]
4. Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma.
Gong J; Yan S; Yu H; Zhang W; Zhang D
Med Sci Monit; 2018 Oct; 24():7586-7594. PubMed ID: 30353907
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
6. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
7. Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma.
Yu DC; Chen XY; Li X; Zhou HY; Yu DQ; Yu XL; Hu YC; Zhang RH; Zhang XB; Zhang K; An JD
Sci Rep; 2021 May; 11(1):11165. PubMed ID: 34045512
[TBL] [Abstract][Full Text] [Related]
8. JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma.
Macedo-Silva C; Miranda-Gonçalves V; Lameirinhas A; Lencart J; Pereira A; Lobo J; Guimarães R; Martins AT; Henrique R; Bravo I; Jerónimo C
Cell Death Dis; 2020 Dec; 11(12):1068. PubMed ID: 33318475
[TBL] [Abstract][Full Text] [Related]
9. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
10. Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study.
Khodaverdian V; Tapadar S; MacDonald IA; Xu Y; Ho PY; Bridges A; Rajpurohit P; Sanghani BA; Fan Y; Thangaraju M; Hathaway NA; Oyelere AK
Sci Rep; 2019 Mar; 9(1):4802. PubMed ID: 30886160
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
12. KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
Hou X; Li Q; Yang L; Yang Z; He J; Li Q; Li D
Exp Biol Med (Maywood); 2021 Sep; 246(17):1869-1883. PubMed ID: 34171978
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
14. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of histone lysine demethylases in prostate cancer.
Crea F; Sun L; Mai A; Chiang YT; Farrar WL; Danesi R; Helgason CD
Mol Cancer; 2012 Aug; 11():52. PubMed ID: 22867098
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Bioinformatics Analysis of Key Methyltransferases and Demethylases for Histone Lysines in Hepatocellular Carcinoma.
Zheng Y; Tang L; Chen G; Liu Z
Technol Cancer Res Treat; 2020; 19():1533033820983284. PubMed ID: 33355042
[TBL] [Abstract][Full Text] [Related]
17. Histone lysine demethylases in breast cancer.
Paolicchi E; Crea F; Farrar WL; Green JE; Danesi R
Crit Rev Oncol Hematol; 2013 May; 86(2):97-103. PubMed ID: 23266085
[TBL] [Abstract][Full Text] [Related]
18. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
19. Histone 3 lysine 4, 9, and 27 demethylases expression profile in fertilized and cloned bovine and porcine embryos.
Glanzner WG; Rissi VB; de Macedo MP; Mujica LKS; Gutierrez K; Bridi A; de Souza JRM; Gonçalves PBD; Bordignon V
Biol Reprod; 2018 Jun; 98(6):742-751. PubMed ID: 29528362
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analyses of Prognostic Values and Immune Infiltration of KDM3 Gene Family in Hepatocellular Carcinoma.
Lin GH; Wu SH; Ko YC; Lin CH; Liao GS; Chen TW; Chen YJ; Hsu KF
Mol Biotechnol; 2023 May; 65(5):752-765. PubMed ID: 36181608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
